A
Axel Ullrich
Researcher at Max Planck Society
Publications - 436
Citations - 63142
Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.
Papers
More filters
Journal ArticleDOI
Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells.
Pao F. Kue,Jason S. Taub,Liza Barki Harrington,Roberto D. Polakiewicz,Axel Ullrich,Yehia Daaka +5 more
TL;DR: In this paper, a positive cooperative interaction between the G protein-coupled lysophosphatidic acid (LPA) and tyrosine kinase epidermal growth factor (EGF) receptors in androgen-insensitive prostate cancer PC-3 cells was shown.
Journal ArticleDOI
A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity
Gy. Kéri,J. Erchegyi,J. Erchegyi,Anikó Horváth,Anikó Horváth,I. Mezö,I. Mezö,M. Idei,Tibor Vántus,Agnes Balogh,Agnes Balogh,Zs. Vadász,Zs. Vadász,Gy. Bökönyi,Gy. Bökönyi,Janos Seprodi,I. Teplán,I. Teplán,O. Csuka,M. Tejeda,D. Gaál,Zs Szegedi,Béla Szende,C. Roze,H. Kalthoff,Axel Ullrich +25 more
TL;DR: In vivo TT-232 was effective on transplanted animal tumors and on human tumor xenografts, and in vitro, it inhibited the proliferation of 20 different human tumor cell lines in the range of 50-95% and induced a very strong apoptosis.
Journal ArticleDOI
The suitability and application of a GFP-actin fusion protein for long-term imaging of the organization and dynamics of the cytoskeleton in mammalian cells.
TL;DR: GFP-actin's fluorescence was used in long-term imaging studies aimed at documenting changes in the cytoskeleton of rat bladder NBT-II carcinoma cells during the 24-hour growth factor-mediated epithelia to mesenchyme transformation.
Journal ArticleDOI
Protein kinase C isoforms β 1 and β 2 inhibit the tyrosine kinase activity of the insulin receptor
TL;DR: The data suggest that the PKC isoforms β 1 and β 2 might be candidates for insulin receptor inhibition, and are suggested to be capable of IRK inhibition.
Journal ArticleDOI
Beyond Herceptin and Gleevec
TL;DR: The approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumours are the first examples of gene-based cancer drugs and represent the first example of a novel strategy in anti-cancer therapy.